An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

More than nine in 10 patients treated with Roche’s next-generation Alzheimer’s disease antibody trontinemab tested negative ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

Novo Nordisk's older oral semaglutide drug failed in late-stage trials aimed at slowing Alzheimer's cognitive decline, ...

Novo Nordisk's oral semaglutide drug failed in late-stage Alzheimer's trials, leading to a 10% drop in share price. The ...

Eli Lilly (LLY) rally comes under scrutiny as Novo Nordisk (NVO) readies key late-stage trial results for its GLP-1 pill ...

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

Oral semaglutide—the ingredient in obesity and diabetes drugs Ozempic and Wegovy—didn’t slow Alzheimer’s disease in two ...

Novo Nordisk shares plunge after its oral semaglutide Alzheimer’s trials fail, raising fresh doubts over its push into a ...

Researchers are reporting that an existing drug can roll back key signs of Alzheimer’s disease in mice, restoring memory ...

Investing.com -- The question of whether Parkinson’s disease is becoming “the next Alzheimer’s” is moving to the center of ...